| scholarly article | Q13442814 |
| P2093 | author name string | Samar A Al-Emadi | |
| Nahid A Qushmaq | |||
| P2860 | cites work | Evidence-based management of thrombosis in the antiphospholipid antibody syndrome | Q28165262 |
| A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 | ||
| High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin | Q28185196 | ||
| A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome | Q28193536 | ||
| Prophylaxis of the antiphospholipid syndrome: a consensus report | Q28196923 | ||
| Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals | Q28210153 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | Q33284736 | ||
| Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients | Q33377847 | ||
| Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients | Q33392824 | ||
| Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus | Q33490967 | ||
| Clinical consequences of antiphospholipid antibodies: an historic cohort study | Q33492364 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug | Q33747286 | ||
| Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort | Q33871715 | ||
| Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis | Q33964007 | ||
| Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies | Q34021321 | ||
| B-cell directed therapies in antiphospholipid antibody syndrome--new directions based on murine and human data | Q34136331 | ||
| Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort | Q34161393 | ||
| Pathogenic mechanisms mediating antiphospholipid syndrome | Q34404108 | ||
| Antiphospholipid antibodies and thrombosis: strength of association | Q35134974 | ||
| 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus | Q36290168 | ||
| Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force | Q36372988 | ||
| Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management | Q36561057 | ||
| Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. | Q37035823 | ||
| Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis | Q37054527 | ||
| Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus | Q37158591 | ||
| Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome | Q37283029 | ||
| New approaches for managing antiphospholipid syndrome | Q37404485 | ||
| Towards evidence-based treatment of thrombotic antiphospholipid syndrome | Q37721614 | ||
| Primary Thrombosis Prophylaxis in Antiphospholipid Antibody–Positive Patients: Where Do We Stand? | Q37812011 | ||
| Clinical course of high-risk patients diagnosed with antiphospholipid syndrome | Q39934417 | ||
| The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. | Q40903111 | ||
| Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. | Q41109148 | ||
| Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis | Q41537096 | ||
| Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual | Q41912319 | ||
| Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 | ||
| The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. | Q41937905 | ||
| Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. | Q41939439 | ||
| Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
| Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients | Q43519903 | ||
| Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. | Q43626449 | ||
| Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients | Q43901099 | ||
| Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. | Q45822025 | ||
| Catastrophic antiphospholipid syndrome (CAPS): update from the 'CAPS Registry'. | Q45912780 | ||
| Rituximab treatment for resistant antiphospholipid syndrome. | Q46427705 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients | Q46443879 | ||
| Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases). | Q46508618 | ||
| Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No. | Q46521769 | ||
| Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups | Q46660881 | ||
| Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis | Q48394757 | ||
| Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. | Q50619255 | ||
| Recurrent miscarriage and long-term thrombosis risk: a case-control study. | Q52054812 | ||
| Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. | Q55547645 | ||
| The blossoming of evidence-based clinical rheumatology: The Arthritis Research Campaign's Clinical Trials Collaboration in association with the MRC Clinical Trials Unit, BSR and BOA | Q57751456 | ||
| High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients With Systemic Lupus Erythematosus | Q62601973 | ||
| Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus | Q68153286 | ||
| Influence of disease duration, continued followup and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus | Q70672339 | ||
| Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry | Q71112355 | ||
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus | Q73167867 | ||
| Primary antiphospholipid syndrome: functional outcome after 10 years | Q73324341 | ||
| Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients | Q74284472 | ||
| The antiphospholipid syndrome | Q77739053 | ||
| [Factors related to the risk of thrombosis in patients with lupus and antiphospholipid antibodies] | Q79187414 | ||
| The two hit hypothesis in the antiphospholipid syndrome: acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS | Q79358178 | ||
| Anti-cardiolipin antibodies and endothelial function in patients with coronary artery disease | Q81033955 | ||
| Antiphospholipid antibodies in patients with coronary artery disease: new cardiac risk factors? | Q81349131 | ||
| Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus | Q81352128 | ||
| Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study | Q82045296 | ||
| Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders | Q84227527 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 348726 | |
| P577 | publication date | 2014-04-17 | |
| P1433 | published in | ISRN rheumatology | Q27723887 |
| P1476 | title | Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety | |
| P478 | volume | 2014 |
| Q57689029 | Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies |
| Q94327168 | Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies |
| Q33776843 | Efficacy of Different Treatment Regimens for Antiphospholipid Syndrome-related Recurrent Spontaneous Abortion |
| Q97535589 | Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update |
| Q89603158 | Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology |
Search more.